AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04563689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)
Description: rinse 15 ml during 1 min during 5 days, twice daily
Study NCT04563689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo rinse
Description: destilled water rinse 15 ml during 1 min during 5 days, twice daily
Study NCT02859779 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: education programs
Description: Four audio-recorded discussion groups will be organized in each of the 10 clinical settings
Study NCT03036761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Description: 3 sessions of auriculotherapy at one month intervals.
Study NCT04120831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection
Description: Drug
Study NCT04120831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept Injection
Description: Drug
Study NCT04700982 — intervention group
Intervention type: OTHER
Intervention: Based on the length of hospital stay
Description: Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and > 3 months (Group 2).Clinical features and functional output will be then compared between the groups.
Study NCT02311010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: daily dose adapted according to Cyp 3A5 polymorphism
Study NCT00549302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
Study NCT00549302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
Study NCT00834860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alpha-2a and ribavirin
Description: They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
Study NCT02986789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In vivo SpHb and PVi Monitoring
Description: Pulse oximeter finger sensor that simultaneously monitors noninvasive hemoglobin (SpHb) and pleth variability index (PVi)
Study NCT03887286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips EPIQ 7 ultrasound machine
Description: Standard transthoracic echocardiography
Study NCT03887286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Lumify Broadband sector array transducer
Description: Portable hand-held ultrasound device
Study NCT00682409 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MR Imaging
Description: MR imaging in the post operative follow-up of cholesteatoma in children
Study NCT04599660 — intervention group
Intervention type: OTHER
Intervention: Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)
Description: This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments
Study NCT02141854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS MDPI
Description: FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
Study NCT02141854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
Study NCT02141854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDPI
Description: The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
Study NCT02141854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salmeterol HFA MDI
Description: Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Study NCT02141854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/salmeterol HFA MDI
Description: Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
Study NCT04108598 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaire
Description: No intervention will be administered, select sites will administer a quality of life questionnaire
Study NCT06071533 — intervention group
Intervention type: DRUG
Intervention: Dandshen
Description: Dandshen injection 20ml /day
Study NCT00670813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil (Vigil)
Description: Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
Study NCT00670813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
Study NCT00369564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glutamic acid
Description: Given orally 3 times daily
Study NCT00369564 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally 3 times daily
Study NCT03174392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Based Training
Description: Resistance based training study: Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
Study NCT03174392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speed Based Training
Description: Speed based training study: Individuals will train at the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
Study NCT01861015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Study NCT01861015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Study NCT02599025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innowalk cycling system
Description: Innowalk is a unique, motorized medical device
Study NCT02599025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APT cycling system
Description: APT is used as a rehabilitative device that cycles the feet automatically or by the individual
Study NCT01972776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBM076
Description: Supplied in 25 mg and 75 mg capsules
Study NCT01972776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study NCT01580306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: Relevant treatment dose capsule (A) for oral administration
Study NCT01580306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: Relevant treatment dose capsule (B) for oral administration
Study NCT04262115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AM-EX
Description: AM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
Study NCT02994953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab (Once weekly)
Description: Participants received avelumab once weekly in combination with M9241 every 4 weeks at M9241 maximum tolerated dose (MTD) for first 12 weeks followed by avelumab once every 2 weeks plus M9241 once every 4 weeks at M9241 MTD until a criterion for treatment discontinuation has been met.
Study NCT04262115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PM-EX
Description: PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
Study NCT02994953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241 (MTD)
Description: Participants received M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.
Study NCT02994953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab (Expansion cohort)
Description: Participants in the expansion cohorts received Induction Therapy (Avelumab once weekly + M9241 once every 4 weeks) through Cycle 3 (for 12 weeks) then starting at Cycle 4, Continuation Therapy (Avelumab once every 2 weeks + M9241 once every 4 weeks).
Study NCT03833271 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine, Immune function
Description: Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.
Study NCT02252549 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPIES+WLI assisted TURB
Study NCT03962413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Approaches To Maxillary Sinus
Description: The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach.
Study NCT00329836 — intervention group
Intervention type: OTHER
Intervention: There are no interventions in the observational study. The symptom of allodynia was measured.
Description: No intervention. Description of allodynia testing appears elsewhere in this document
Study NCT01427829 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Computer-assisted Psychosocial Risk Assessment (CaPRA)
Description: The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
Study NCT01427829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted Psychosocial Risk Assessment (CaPRA)
Description: The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
Study NCT03449186 — intervention group
Intervention type: OTHER
Intervention: Saliva collection
Study NCT03449186 — intervention group
Intervention type: OTHER
Intervention: GCF collection
Study NCT02252549 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WLI assisted TURB
Study NCT01957033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and education once/week for 6 weeks
Description: Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book
Study NCT01957033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and education twice/week for 6 weeks
Description: Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
Study NCT01742910 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraocular lens implantation
Study NCT01957033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and education 3 times/week for 6 weeks
Description: Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
Study NCT01957033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy once/week for 3 weeks
Description: Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
Study NCT01957033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy twice/week for 3 weeks
Description: Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
Study NCT01957033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy 3 times/week for 3 weeks
Description: Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
Study NCT01957033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy once/week for 6 weeks
Description: Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
Study NCT01957033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy twice/week for 6 weeks
Description: Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
Study NCT01957033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy 3 times/week for 6 weeks
Description: Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
Study NCT04297124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90009
Description: 0.6 mg \[ 14C\]-CC-90009 administered IV as a single dose
Study NCT04297124 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [14C]
Description: A single dose of \[ 14C\]-CC-90009 will contain approximately 2 µCi of radioactivity.
Study NCT01694459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Description: Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
Study NCT01694459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose heparin
Description: Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
Study NCT02583100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Feedback
Description: (1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.
Study NCT02583100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Feedback
Description: (1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
Study NCT00359203 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dual chamber pacemeker
Study NCT03153644 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: 1 hour semi-structured
Study NCT03153644 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observation
Description: Field Observation
Study NCT00913991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Training
Description: Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
Study NCT00913991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Training
Description: Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
Study NCT00873535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
Study NCT00873535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
Study NCT03649659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: SDF will be applied twice during the study
Study NCT03649659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is being compared to the SDF and will also be applied twice
Study NCT00359203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual chamber pacemeker
Study NCT02912247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection
Description: human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once
Study NCT04441658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
Study NCT04441658 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline containing human albumin will be infused to the control group
Study NCT03453944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VentFree prototype (VF03-K) active stimulation
Description: Abdominal wall muscle stimulation synchronised with mechanical ventilation. Stimulation frequency: 30 Hz, pulse width: 352us, max. intensity: 100mA (threshold intensity determined using ultrasound)